

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/058605 A1

(51) International Patent Classification:

A61K 31/40 (2006.01) *A61K 31/513* (2006.01)
A61K 31/4015 (2006.01) *A61K 45/06* (2006.01)
A61K 31/451 (2006.01) *A61P 35/02* (2006.01)
A61K 31/496 (2006.01) *A61P 43/00* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/075896

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

21 September 2021 (21.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20197230.4 21 September 2020 (21.09.2020) EP
21184448.5 08 July 2021 (08.07.2021) EP

(71) Applicants: **ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG** [DE/DE]; Friedrichstrasse 39, 79098 Freiburg (DE). **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **ZEISER, Robert**; Lise Meitner Str. 10, 79100 Freiburg (DE). **DUYSTER, Justus**; Tennenbacher Str. 9, 79106 Freiburg (DE). **MENSSEN, Hans Dietrich**; c/o Novartis AG, Lichtstrasse 35, 4056 Basel (CH).

(74) Agent: **HERTIN UND PARTNER RECHTS- UND PATENTANWÄLTE**; Kurfürstendamm 54/55, 10707 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,



WO 2022/058605 A1

(54) Title: MDM2 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF HEMATOLOGIC NEOPLASM RELAPSE AFTER HEMATOPOIETIC CELL TRANSPLANTATION

(57) Abstract: The invention relates to a mouse double minute 2 (MDM2) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient. In embodiments, the hematologic neoplasm is a leukaemia, preferably acute myeloid leukaemia (AML). Preferably, the patient received an allogeneic T cell transplantation, either together with the HCT and/or after HCT, such as at the time point of MDM2 administration. Furthermore, the invention relates to a pharmaceutical composition comprising a MDM2 inhibitor and an exportin 1 (XPO-1) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient according to any of the preceding claims.